Sudeep Pharma’s Rs 895-crore IPO enters its final bidding day with strong overall demand, led by robust NII and retail participation. Despite a softening grey-market premium, subscription momentum remains healthy. Backed by diversified excipient capabilities, steady financial growth and anchor interest, the company is positioned favourably as it approaches allotment and listing. Source link India News Dharmesh Kant sees NTPC Green as… Execution hurdles remain a big… Why has a volcano 4,000 kms away… Zubeen Garg’s death was a… Stock Market Agilent outlines 4%–6% core… Fed Cuts a Concern Given Inflation… 'Takaichi cannot retract her… Excelsoft Tech IPO to…